
Title:
Metronidazole
Text:
Antibiotic and antiprotozoal medication


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}MetronidazoleLegal statusLegal status
AU: S4 (Prescription only) 
CA:  ℞-only 
UK: POM (Prescription only) 
US: ℞-only 
Pharmacokinetic dataBioavailability80% (by mouth), 60–80% (rectal), 20–25% (vaginal)[1][2][3]Protein binding20%[1][2]MetabolismLiver[1][2]MetabolitesHydroxymetronidazoleElimination half-life8 hours[1][2]ExcretionUrine (77%), faeces (14%)[1][2]Identifiers
IUPAC name
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol
CAS Number443-48-1 YPubChem CID4173DrugBankDB00916 YChemSpider4029 YUNII140QMO216EKEGGD00409 YChEBICHEBI:6909 YChEMBLChEMBL137 YNIAID ChemDB007953PDB ligand2MN (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID2020892 ECHA InfoCard100.006.489 Chemical and physical dataFormulaC6H9N3O3Molar mass171.156 g·mol−13D model (JSmol)Interactive imageMelting point159 to 163 °C (318 to 325 °F)
SMILES
OCCn1c(C)ncc1[N+](=O)[O-]

InChI
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 YKey:VAOCPAMSLUNLGC-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Metronidazole, marketed under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication.[4] It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis.[4] It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.[4] It is an option for a first episode of mild-to-moderate Clostridium difficile colitis if vancomycin or fidaxomicin is unavailable.[4][5] Metronidazole is available by mouth, as a cream, and by injection into a vein.[4]
Common side effects include nausea, a metallic taste, loss of appetite, and headaches.[4] Occasionally seizures or allergies to the medication may occur.[4] Some state that metronidazole should not be used in early pregnancy, while others state doses for trichomoniasis are safe.[6] Metronidazole is generally considered compatible with breastfeeding.[6][7]
Metronidazole began to be commercially used in 1960 in France.[8] It is on the World Health Organization's List of Essential Medicines.[9] It is available in most areas of the world.[10] In 2019, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[11][12]

Contents

1 Medical uses

1.1 Bacterial vaginosis
1.2 Trichomoniasis
1.3 Giardiasis
1.4 Dracunculus
1.5 C. difficile colitis
1.6 E. histolytica
1.7 Preterm births
1.8 Hypoxic radiosensitizer
1.9 Perioral dermatitis


2 Adverse effects

2.1 Mutagenesis and carcinogenesis
2.2 Stevens–Johnson syndrome


3 Drug interactions

3.1 Alcohol
3.2 Other drug interactions


4 Pharmacology

4.1 Mechanism of action
4.2 Pharmacokinetics


5 History
6 Brand name
7 Synthesis
8 Veterinary use
9 References
10 External links



Medical uses[edit]
  A tube of metronidazole
Metronidazole is primarily used to treat: bacterial vaginosis, pelvic inflammatory disease (along with other antibacterials like ceftriaxone), pseudomembranous colitis, aspiration pneumonia, rosacea (topical), fungating wounds (topical), intra-abdominal infections, lung abscess, periodontitis, amoebiasis, oral infections, giardiasis, trichomoniasis, and infections caused by susceptible anaerobic organisms such as Bacteroides, Fusobacterium, Clostridium, Peptostreptococcus, and Prevotella species.[13] It is also often used to eradicate Helicobacter pylori along with other drugs and to prevent infection in people recovering from surgery.[13]
Metronidazole is bitter and so the liquid suspension contains metronidazole benzoate. This may require hydrolysis in the gastrointestinal tract and some sources speculate that it may be unsuitable in people with diarrhea or feeding-tubes in the duodenum or jejunum.[14][15]

Bacterial vaginosis[edit]
Drugs of choice for the treatment of bacterial vaginosis include metronidazole and clindamycin. The treatment of choice for bacterial vaginosis in nonpregnant women include metronidazole oral twice daily for seven days, or metronidazole gel intravaginally once daily for five days, or clindamycin intravaginally at bedtime for seven days. For pregnant women, the treatment of choice is metronidazole oral three times a day for seven days. Data does not report routine treatment of male sexual partners.[16]

Trichomoniasis[edit]
The 5-nitroimidazole drugs (metronidazole and tinidazole) are the mainstay of treatment for infection with Trichomonas vaginalis. Treatment for both the infected patient and the patient's sexual partner is recommended, even if asymptomatic. Therapy other than 5-nitroimidazole drugs is also an option, but cure rates are much lower.[17]

Giardiasis[edit]
Oral metronidazole is a treatment option for giardiasis, however, the increasing incidence of nitroimidazole resistance is leading to the increased use of other compound classes.[18]

Dracunculus[edit]
In the case of Dracunculus medinensis (Guinea worm), metronidazole just eases worm extraction rather than killing the worm.[4]

C. difficile colitis[edit]
Initial antibiotic therapy for less-severe Clostridioides difficile infection colitis (pseudomembranous colitis) consists of metronidazole,  vancomycin, or fidaxomicin by mouth.[5] In 2017, the IDSA generally recommended vancomycin and fidaxomicin over metronidazole.[5] Vancomycin by mouth has been shown to be more effective in treating people with severe C. difficile colitis.[19]

E. histolytica[edit]
Entamoeba histolytica invasive amebiasis is treated with metronidazole for eradication, in combination with diloxanide to prevent recurrence.[20] Although it is generally a standard treatment it is associated with some side effects.[21]

Preterm births[edit]
Metronidazole has also been used in women to prevent preterm birth associated with bacterial vaginosis, amongst other risk factors including the presence of cervicovaginal fetal fibronectin (fFN). Metronidazole was ineffective in preventing preterm delivery in high-risk pregnant women (selected by history and a positive fFN test) and, conversely, the incidence of preterm delivery was found to be higher in women treated with metronidazole.[22]

Hypoxic radiosensitizer[edit]
In addition to its anti-biotic properties, attempts were also made to use a possible radiation-sensitizing effect of metronidazole in the context of radiation therapy against hypoxic tumors.[23] However, the neurotoxic side effects occurring at the required dosages have prevented the widespread use of metronidazole as an adjuvant agent in radiation therapy.[24] However, other nitroimidazoles derived from metronidazole such as nimorazole with reduced electron affinity showed less serious neuronal side effects and have found their way into radio-onological practice for head and neck tumors in some countries.[25]

Perioral dermatitis[edit]
Canadian Family Physician has recommended topical metronidazole as a third-line treatment for the perioral dermatitis either along with or without oral tetracycline or oral erythromycin as first and second line treatment respectively.[26][27]

Adverse effects[edit]
Common adverse drug reactions (≥1% of those treated with the drug) associated with systemic metronidazole therapy include: nausea, diarrhea, weight loss, abdominal pain, vomiting, headache, dizziness, and metallic taste in the mouth. Intravenous administration is commonly associated with thrombophlebitis. Infrequent adverse effects include: hypersensitivity reactions (rash, itch, flushing, fever), headache, dizziness, vomiting, glossitis, stomatitis, dark urine, and paraesthesia.[13] High doses and long-term systemic treatment with metronidazole are associated with the development of leucopenia, neutropenia, increased risk of peripheral neuropathy, and central nervous system toxicity.[13]  Common adverse drug reaction associated with topical metronidazole therapy include local redness, dryness and skin irritation; and eye watering (if applied near eyes).[13][28] Metronidazole has been associated with cancer in animal studies.[29][failed verification] In rare cases, it can also cause temporary hearing loss that reverses after cessation of the treatment.[30][31]
Some evidence from studies in rats indicates the possibility it may contribute to serotonin syndrome, although no case reports documenting this have been published to date.[32][33]

Mutagenesis and carcinogenesis[edit]
Metronidazole is listed by the U.S. National Toxicology Program (NTP) as reasonably anticipated to be a human carcinogen.[34] Although some of the testing methods have been questioned, oral exposure has been shown to cause cancer in experimental animals and has also demonstrated some mutagenic effects in bacterial cultures.[34][35] The relationship between exposure to metronidazole and human cancer is unclear.[34][36] One study [37] found an excess in lung cancer among women (even after adjusting for smoking), while other studies [38][39][40] found either no increased risk, or a statistically insignificant risk.[34][41]
Metronidazole is listed as a possible carcinogen according to the World Health Organization (WHO) International Agency for Research on Cancer (IARC).[42] A study in those with Crohn's disease also found chromosomal abnormalities in circulating lymphocytes in people treated with metronidazole.[35]

Stevens–Johnson syndrome[edit]
Metronidazole alone rarely causes Stevens–Johnson syndrome, but is reported to occur at high rates when combined with mebendazole.[43]

Drug interactions[edit]
Alcohol[edit]
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}See also: Disulfiram-like drug
Consuming alcohol while taking metronidazole has been suspected in case reports to cause a disulfiram-like reaction with effects that can include nausea, vomiting, flushing of the skin, tachycardia, and shortness of breath.[44] People are often advised not to drink alcohol during systemic metronidazole therapy and for at least 48 hours after completion of treatment.[13] However, some studies call into question the mechanism of the interaction of alcohol and metronidazole,[45][46][47]
and a possible central toxic serotonin reaction for the alcohol intolerance is suggested.[32] Metronidazole is also generally thought to inhibit the liver metabolism of propylene glycol (found in some foods, medicines, and in many electronic cigarette e-liquids), thus propylene glycol may potentially have similar interaction effects with metronidazole.[medical citation needed]

Other drug interactions[edit]
Metronidazole is a moderate CYP2C9 inhibitor. CYP2C9 is an enzyme of cytochrome P450 family. Therefore, metronidazole may interact with medications metabolized by this enzyme.[48][49][50] Examples of such medications are lomitapide, warfarin, etc.[1]

Pharmacology[edit]
Mechanism of action[edit]
Metronidazole is of the nitroimidazole class. It inhibits nucleic acid synthesis by forming nitroso radicals, which disrupt the DNA of microbial cells.[1][51] This function only occurs when metronidazole is partially reduced, and because this reduction usually happens only in anaerobic bacteria and protozoans, it has relatively little effect upon human cells or aerobic bacteria.[52]

Pharmacokinetics[edit]
  Hydroxymetronidazole, the main metabolite
Oral metronidazole is approximately 80% bioavailable via the gut and peak blood plasma concentrations occur after one to two hours. Food may slow down absorption but does not diminish it. Of the circulating substance, about 20% is bound to plasma proteins. It penetrates well into tissues, the cerebrospinal fluid, the amniotic fluid and breast milk, as well as into abscess cavities.[51]
About 60% of the metronidazole is metabolized by oxidation to the main metabolite hydroxymetronidazole and a carboxylic acid derivative, and by glucuronidation. The metabolites show antibiotic and antiprotozoal activity in vitro.[51] Metronidazole and its metabolites are mainly excreted via the kidneys (77%) and to a lesser extent via the faeces (14%).[1][2] The biological half-life of metronidazole in healthy adults is eight hours, in infants during the first two months of their lives about 23 hours, and in premature babies up to 100 hours.[51]
The biological activity of hydroxymetronidazole is 30% to 65%, and the elimination half-life is longer than that of the parent compound.[53] The serum half-life of hydroxymetronidazole after suppository was 10 hours, 19 hours after intravenous infusion, and 11 hours after a tablet.[54]

History[edit]
The drug was initially developed by Rhône-Poulenc in the 1950s[55] and licensed to G.D. Searle.[56] Searle was acquired by Pfizer in 2003.[57] The original patent expired in 1982, but evergreening reformulation occurred thereafter.[58]

Brand name[edit]
In India, it is sold under the brand name Metrogyl and Flagyl.[59] In Bangladesh, it is available as Amodis, Amotrex, Dirozyl, Filmet, Flagyl, Flamyd, Metra, Metrodol, Metryl, etc.[60]

Synthesis[edit]
2-Methylimidazole (1) may be prepared via the Debus-Radziszewski imidazole synthesis, or from ethylenediamine and acetic acid, followed by treatment with lime, then Raney nickel. 2-Methylimidazole is nitrated to give 2-methyl-4(5)-nitroimidazole (2), which is in turn alkylated with ethylene oxide or 2-chloroethanol to give metronidazole (3):[61][62][63]


Veterinary use[edit]
Metronidazole  is widely used to treat infections of Giardia in dogs, cats, and other companion animals, although it does not reliably clear infection with this organism and is being supplanted by fenbendazole for this purpose in dogs and cats.[64] It is also used for the management of chronic inflammatory bowel disease in cats and dogs.[65] Another common usage is the treatment of systemic and/or gastrointestinal clostridial infections in horses. Metronidazole is used in the aquarium hobby to treat ornamental fish and as a broad-spectrum treatment for bacterial and protozoan infections in reptiles and amphibians. In general, the veterinary community may use metronidazole for any potentially susceptible anaerobic infection. The U.S. Food and Drug Administration (FDA) suggests it only be used when necessary because it has been shown to be carcinogenic in mice and rats, as well as to prevent antimicrobial resistance.[66][67]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c d e f g h .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Flagyl, Flagyl ER (metronidazole) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 7 April 2014. Retrieved 3 April 2014.

^ Jump up to: a b c d e f Brayfield, A, ed. (14 January 2014). "Metronidazole". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 3 April 2014.[dead link]

^ Brayfield A, ed. (2017). Martindale: The Complete Drug Reference (39th ed.). London: Pharmaceutical Press. ISBN 978-0-85711-309-2.

^ Jump up to: a b c d e f g h "Metronidazole". The American Society of Health-System Pharmacists. Archived from the original on 6 September 2015. Retrieved 31 July 2015.

^ Jump up to: a b c McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE,  et al. (March 2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)". Clinical Infectious Diseases. 66 (7): e1–e48. doi:10.1093/cid/cix1085. PMC 6018983. PMID 29462280.

^ Jump up to: a b "Metronidazole Use During Pregnancy". www.drugs.com. Archived from the original on 1 January 2017. Retrieved 1 January 2017.

^ "Safety in Lactation: Metronidazole and tinidazole". SPS - Specialist Pharmacy Service. Retrieved 22 February 2020.

^ Corey EJ (2013). Drug discovery practices, processes, and perspectives. Hoboken, N.J.: John Wiley & Sons. p. 27. ISBN 9781118354469. Archived from the original on 8 September 2017.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ Schmid G (28 July 2003). "Trichomoniasis treatment in women". Archived from the original on 1 August 2015. Retrieved 1 August 2015.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Metronidazole - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ Jump up to: a b c d e f Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

^ Orla Geoghegan, Christopher Eades, Luke SP Moore, Mark Gilchrist (9 February 2017). "Clostridium difficile: diagnosis and treatment update". The Pharmaceutical Journal. Royal Pharmaceutical Society.{{cite web}}:  CS1 maint: multiple names: authors list (link)

^ Dickman A (2012). Drugs in Palliative Care. OUP Oxford. p. 355. ISBN 9780191636103.

^ Joesoef MR, Schmid GP, Hillier SL (January 1999). "Bacterial vaginosis: review of treatment options and potential clinical indications for therapy". Clinical Infectious Diseases. 28 Suppl 1: S57-65. doi:10.1086/514725. PMID 10028110.

^ duBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM (March 1997). "Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis". Sexually Transmitted Diseases. 24 (3): 156–60. doi:10.1097/00007435-199703000-00006. PMID 9132982. S2CID 6617019.

^ Leitsch D (September 2015). "Giardia lamblia". Current Tropical Medicine Reports. 2 (3): 128–135. doi:10.1007/s40475-015-0051-1. PMC 4523694. PMID 26258002.

^ Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (August 2007). "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity". Clinical Infectious Diseases. 45 (3): 302–7. doi:10.1086/519265. PMID 17599306.

^ Ryan KJ, Ahmad N, Andrew Alspaugh J, Lawrence Drew W, Lagunoff M, Pottinger P, Barth Reller L, Reller ME, Sterling CR, Weissman S (12 January 2018). Sherris medical microbiology. Ryan, Kenneth J. (Kenneth James), 1940- (Seventh ed.). New York. ISBN 9781259859816. OCLC 1004770160.

^ Rawat A, Singh P, Jyoti A, Kaushik S, Srivastava VK (August 2020). "Averting transmission: A pivotal target to manage amoebiasis". Chemical Biology & Drug Design. 96 (2): 731–744. doi:10.1111/cbdd.13699. PMID 32356312. S2CID 218475533.

^ Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G,  et al. (January 2006). "General obstetrics: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study". BJOG. 113 (1): 65–74. doi:10.1111/j.1471-0528.2005.00788.x. PMID 16398774. S2CID 11366650.

^ D. Nori, J. M. Cain, B. S. Hilaris, W. B. Jones, J. L. Lewis: Metronidazole as a radiosensitizer and high-dose radiation in advanced vulvovaginal malignancies, a pilot study. In: Gynecologic Oncology. vol 16, issue 1, August 1983, S. 117–128, ISSN 0090-8258, PMID 6884824.

^ J.R.Sarna, S.Furtado, A.K.Brownell: Neurologic complications of metronidazole. In: Can J Neurol Sci. vol 40, issue 6, November 2013, S. 768-776, PMID 24257215.

^ J.Overgaard, H.S.Hansen, M.Overgaard, L.Bastholt, A.Berthelsen, L.Specht, et al:A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) In: Radiother Oncol vol 46, issue 2, May 1998, PMID 9510041.

^ Cheung, Melody J.; Taher, Muba; Lauzon, Gilles J. (April 2005). "Acneiform facial eruptions: a problem for young women". Canadian Family Physician. 51: 527–533. ISSN 0008-350X. PMC 1472951. PMID 15856972.

^ Cheung, Melody J.; Taher, Muba; Lauzon, Gilles J. (1 April 2005). "Acneiform facial eruptions: a problem for young women". Canadian Family Physician. 51 (4): 527–533. ISSN 0008-350X. PMC 1472951. PMID 15856972.

^ Side Effects

^ "Flagyl metronidazole tablets label" (PDF). Archived (PDF) from the original on 22 January 2016. Retrieved 5 August 2015.

^ Iqbal SM, Murthy JG, Banerjee PK, Vishwanathan KA (April 1999). "Metronidazole ototoxicity--report of two cases". The Journal of Laryngology and Otology. 113 (4): 355–7. doi:10.1017/s0022215100143968. PMID 10474673.

^ Lawford R, Sorrell TC (August 1994). "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report". Clinical Infectious Diseases. 19 (2): 346–8. doi:10.1093/clinids/19.2.346. PMID 7986915.

^ Jump up to: a b Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T,  et al. (2007). "Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines". International Journal of Toxicology. 26 (5): 423–32. doi:10.1080/10915810701583010. PMID 17963129. S2CID 41230661.

^ Karamanakos PN (November 2008). "The possibility of serotonin syndrome brought about by the use of metronidazole". Minerva Anestesiologica. 74 (11): 679. PMID 18971895.

^ Jump up to: a b c d National Toxicology Program (2016). "Metronidazole" (PDF). Report on Carcinogens (Fourteenth ed.). National Toxicology Program (NTP). Archived (PDF) from the original on 9 February 2020. Retrieved 9 February 2020.

^ Jump up to: a b "Metrogyl Metronidazole Product Information" (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 8 May 2013. Archived from the original on 9 September 2016. Retrieved 3 April 2014.

^ Bendesky A, Menéndez D, Ostrosky-Wegman P (June 2002). "Is metronidazole carcinogenic?". Mutation Research. 511 (2): 133–44. doi:10.1016/S1383-5742(02)00007-8. PMID 12052431.

^ Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC (February 1988). "Cancer after exposure to metronidazole". Mayo Clin. Proc. 63 (2): 147–53. doi:10.1016/s0025-6196(12)64947-7. ISSN 0025-6196. PMID 3339906.

^ "Metronidazole (IARC Summary & Evaluation, Supplement7, 1987)". INCHEM2. 3 March 1998. Retrieved 12 September 2019.

^ Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF, Roberson P, Pais R, Ray WA (October 1998). "Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years". Cancer. 83 (7): 1461–8. doi:10.1002/(sici)1097-0142(19981001)83:7<1461::aid-cncr25>3.0.co;2-1. PMID 9762949.

^ Friedman GD, Jiang SF, Udaltsova N, Quesenberry CP, Chan J, Habel LA (November 2009). "Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity". Int. J. Cancer. 125 (9): 2173–8. doi:10.1002/ijc.24545. ISSN 0020-7136. PMC 2759691. PMID 19585498.

^ "Flagyl 375 U.S. Prescribing Information" (PDF). Pfizer. Archived from the original (PDF) on 7 August 2008.

^ "Agents Classified by the IARC Monographs, Volumes 1–124". International Agency for Research on Cancer (IARC). 8 July 2019. Archived from the original on 6 September 2019. Retrieved 12 September 2019.

^ Chen KT, Twu SJ, Chang HJ, Lin RS (March 2003). "Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan". American Journal of Public Health. 93 (3): 489–92. doi:10.2105/ajph.93.3.489. PMC 1447769. PMID 12604501.

^ Cina SJ, Russell RA, Conradi SE (December 1996). "Sudden death due to metronidazole/ethanol interaction". The American Journal of Forensic Medicine and Pathology. 17 (4): 343–6. doi:10.1097/00000433-199612000-00013. PMID 8947362.

^ Gupta NK, Woodley CL, Fried R (October 1970). "Effect of metronidazole on liver alcohol dehydrogenase". Biochemical Pharmacology. 19 (10): 2805–8. doi:10.1016/0006-2952(70)90108-5. PMID 4320226.

^ 
Williams CS, Woodcock KR (February 2000). "Do ethanol and metronidazole interact to produce a disulfiram-like reaction?". The Annals of Pharmacotherapy. 34 (2): 255–7. doi:10.1345/aph.19118. PMID 10676835. S2CID 21151432. the authors of all the reports presumed the metronidazole-ethanol reaction to be an established pharmacologic fact. None provided evidence that could justify their conclusions

^ Visapää JP, Tillonen JS, Kaihovaara PS, Salaspuro MP (June 2002). "Lack of disulfiram-like reaction with metronidazole and ethanol". The Annals of Pharmacotherapy. 36 (6): 971–4. doi:10.1345/1542-6270(2002)036<0971:lodlrw>2.0.co;2. PMID 12022894.

^ Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine.

^ Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K (2015). "Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes". Xenobiotica. 45 (5): 413–419. doi:10.3109/00498254.2014.990948. PMID 25470432. S2CID 26910995.

^ Tirkkonen T, Heikkilä P, Huupponen R, Laine K (2010). "Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide". Journal of Internal Medicine. 268 (4): 359–366. doi:10.1111/j.1365-2796.2010.02257.x. PMID 20698928. S2CID 45449460.

^ Jump up to: a b c d Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Anaerobex-Filmtabletten.

^ 
Eisenstein BI, Schaechter M (2007). "DNA and Chromosome Mechanics".  In Schaechter M, Engleberg NC, DiRita VJ, Dermody T (eds.). Schaechter's Mechanisms of Microbial Disease. Hagerstown, MD: Lippincott Williams & Wilkins. p. 28. ISBN 978-0-7817-5342-5.

^ . PMID 10384859. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

^ . PMID 6588489. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

^ Quirke V (29 December 2014). "Targeting the American market for medicines, ca. 1950s-1970s: ICI and Rhône-Poulenc compared". Bulletin of the History of Medicine. 88 (4): 654–96. doi:10.1353/bhm.2014.0075. PMC 4335572. PMID 25557515.

^ "G.D. SEARLE & CO. v. COMM | 88 T.C. 252 (1987) | 8otc2521326 | Leagle.com". Leagle. Retrieved 18 June 2019.

^ "2003:Pfizer and Pharmacia Merger". Pfizer.

^ Dickson S (July 2019). "Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016". Journal of Managed Care & Specialty Pharmacy. 25 (7): 780–792. doi:10.18553/jmcp.2019.18366. PMID 30799664.

^ "Metrogyl ER". Medical Dialogues. Retrieved 1 March 2021.

^ "Metronidazole Brands". Medex. Retrieved 24 November 2021.

^ Ebel K, Koehler H, Gamer AO, Jäckh R. "Imidazole and Derivatives". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a13_661.

^ Actor P, Chow AW, Dutko FJ, McKinlay MA. "Chemotherapeutics". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a06_173.

^ Kraft MY, Kochergin PM, Tsyganova AM, Shlikhunova VS (1989). "Synthesis of metronidazole from ethylenediamine". Pharmaceutical Chemistry Journal. 23 (10): 861–863. doi:10.1007/BF00764821. S2CID 38187002.

^ Barr SC, Bowman DD, Heller RL (July 1994). "Efficacy of fenbendazole against giardiasis in dogs". American Journal of Veterinary Research. 55 (7): 988–90. PMID 7978640.

^ Hoskins JD (1 October 2001). "Advances in managing inflammatory bowel disease". DVM Newsmagazine. Archived from the original on 31 December 2013. Retrieved 28 December 2013.

^ Plumb DC (2008). Veterinary Drug Handbook (6th ed.). Wiley. ISBN 978-0-8138-2056-9.

^ "Metronidazole". Drugs.com. Archived from the original on 24 June 2013.


External links[edit]
"Metronidazole". Drug Information Portal. U.S. National Library of Medicine.
"Metronidazole". Merck manuals.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteStomatological preparations (A01)Caries prophylaxis
Dectaflur
Olaflur
Sodium fluoride
Sodium monofluorophosphate
Stannous fluoride
Infection and antiseptics
Amphotericin B
Benzoxonium chloride
Chlorhexidine
Chlortetracycline
Clotrimazole
Cetylpyridinium chloride
Domiphen bromide
Doxycycline
Eugenol
Hexetidine
Hydrogen peroxide
Mepartricin
Metronidazole
Miconazole
Minocycline
Natamycin
Neomycin
Oxyquinoline
Polynoxylin
Sodium perborate
Tetracycline
Tibezonium iodide
Corticosteroids (Glucocorticoids)
Dexamethasone
Hydrocortisone
Triamcinolone
Other
Amlexanox
Acetylsalicylic acid
Becaplermin
Benzydamine
Epinephrine/Adrenalone

vteAntibiotics and chemotherapeutics for dermatological use (D06)AntibioticsTetracycline and derivatives
Demeclocycline
Chlortetracycline
Oxytetracycline
Tetracycline
Others
Amphenicol: Chloramphenicol
Aminoglycosides: Neomycin
Gentamicin
Amikacin
Quinolones: Nadifloxacin
Streptogramin: Virginiamycin
Rifamycin: Rifaximin
other: Fusidic acid
Bacitracin
Tyrothricin
Mupirocin
ChemotherapeuticsSulfonamides
Silver sulfadiazine
Sulfathiazole
Mafenide
Sulfamethizole
Sulfanilamide
Sulfamerazine
Antivirals
Aciclovir
Penciclovir
Idoxuridine
Edoxudine
Imiquimod
Resiquimod
Podophyllotoxin
Docosanol
Tromantadine
Inosine
Lysozyme
Ibacitabine
Lysine
Other
Ingenol mebutate
Metronidazole
Tirbanibulin

vteGynecological anti-infectives and antiseptics (G01)Antibiotics
Candicidin
Chloramphenicol
Hachimycin
Oxytetracycline
Carfecillin
Mepartricin
Clindamycin
Pentamycin
Arsenic compounds
Acetarsol
Quinoline derivatives
Diiodohydroxyquinoline
Clioquinol
Chlorquinaldol
Dequalinium
Broxyquinoline
Oxyquinoline
Organic acids
Lactic acid
Acetic acid
Ascorbic acid
Sulfonamides
Sulfatolamide
AntifungalsImidazoles
Metronidazole
Clotrimazole
Miconazole
Econazole
Ornidazole
Isoconazole
Tioconazole
Ketoconazole
Fenticonazole
Azanidazole
Propenidazole
Butoconazole
Omoconazole
Oxiconazole
Flutrimazole
Triazoles
Terconazole
Polyenes
Nystatin
Natamycin
Amphotericin B
Other
Ciclopirox
Methylrosaniline
Other
Clodantoin
Inosine
Policresulen
Nifuratel
Furazolidone
Povidone-iodine
Protiofate
Lactobacillus fermentum
Copper usnate

vteAntibacterials that inhibit nucleic acid (J01E, J01M)Antifolates(inhibit bacterialpurine metabolism,thereby inhibitingDNA and RNAsynthesis)DHFR inhibitor
2,4-Diaminopyrimidine
Brodimoprim
Iclaprim†
Ormetoprim
Pyrimethamine#
Tetroxoprim
Trimethoprim#
Sulfonamides(DHPS inhibitor)Short-acting
Sulfaisodimidine
Sulfamethizole
Sulfadimidine
Sulfapyridine (Sulfasalazine)
Sulfafurazole (Acetyl sulfisoxazole)
Sulfanilamide
Prontosil
Sulfathiazole (Phthalylsulfathiazole, Succinylsulfathiazole)
Sulfathiourea
Intermediate-acting
Sulfamethoxazole
Sulfadiazine#
Sulfamoxole
Long-acting
Sulfadimethoxine
Sulfadoxine
Sulfalene
Sulfametomidine
Sulfametoxydiazine
Sulfamethoxypyridazine
Sulfaperin
Sulfamerazine
Sulfaphenazole
Sulfamazone
Other/ungrouped
Sulfacetamide
Sulfaclozine
Sulfadicramide
Sulfaguanidine
Sulfametrole
Sulfanitran
Combinations
Trimethoprim/sulfamethoxazole#
Ormetoprim/sulfadimethoxine
Pyrimethamine/dapsone
Pyrimethamine/sulfadoxine
Other DHPS inhibitors
Acediasulfone
Dapsone
Solasulfone
Sulfoxone
Quinolones(inhibit bacterialtopoisomeraseand/or DNA gyrase,thereby inhibitingDNA replication)1st generation
Cinoxacin‡
Flumequine‡
Nalidixic acid‡
Oxolinic acid‡
Pipemidic acid‡
Piromidic acid‡
Rosoxacin‡
Fluoroquinolones2nd generation
Ciprofloxacin#
Ofloxacin
Enoxacin‡
Fleroxacin‡
Lomefloxacin‡
Nadifloxacin‡
Norfloxacin‡
Pefloxacin‡
Rufloxacin‡
3rd generation
Levofloxacin#
Balofloxacin‡
Grepafloxacin‡
Pazufloxacin‡
Sparfloxacin‡
Temafloxacin‡
Tosufloxacin‡
4th generation
Besifloxacin
Delafloxacin
Gatifloxacin
Finafloxacin
Gemifloxacin
Moxifloxacin#
Clinafloxacin†
Garenoxacin‡
Prulifloxacin‡
Sitafloxacin‡
Trovafloxacin‡/Alatrofloxacin‡
Veterinary
Danofloxacin
Difloxacin
Enrofloxacin
Ibafloxacin
Marbofloxacin
Orbifloxacin
Pradofloxacin
Sarafloxacin‡
Newer non-fluorinated
Nemonoxacin
Related (DG)
Aminocoumarins: Novobiocin
Anaerobic DNAinhibitorsNitroimidazole derivatives
Metronidazole#
Ornidazole
Secnidazole
Tinidazole
Nitrofuran derivatives
Furazolidone‡
Nifuroxazide
Nifurtoinol
Nifurzide
Nitrofurantoin#
Nitrofurazone
RNA synthesisRifamycins/RNA polymerase
Rifampicin#
Rifabutin#
Rifapentine#
Rifaximin
Rifalazil§
Lipiarmycins
Fidaxomicin

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteAntiparasitics – antiprotozoal agents – Chromalveolata antiparasitics (P01)Alveo-lateApicom-plexaConoidasida/(Coccidiostats)Cryptosporidiosis
thiazolides (nitazoxanide)
Isosporiasis
trimethoprim/sulfamethoxazole#
Toxoplasmosis
pyrimethamine
sulfadiazine
clindamycin
atovaquone
AconoidasidaMalariaIndividual agentsHemozoininhibitorsAminoquinolines
(4-): amodiaquine#
chloroquine#
hydroxychloroquine#
(8-): primaquine#
pamaquine‡
tafenoquine
4-Methanolquinolines
mefloquine#
quinine#
quinidine
Other
lumefantrine
+ artemether#
halofantrine
AntifolatesDHFR inhibitors
pyrimethamine
cycloguanil
biguanides
chlorproguanil
proguanil#
Sulfonamides
sulfadoxine
sulfalene
Co-formulation
sulfadoxine/pyrimethamine (SP)#
Sesquiterpenelactones
artemether#
artemisinin
artemotil
artesunate#
dihydroartemisinin
Other
atovaquone (+ proguanil)
tetracycline
doxycycline#
clindamycin
mepacrine
pyronaridine
piperaquine
Combi-nationsFixed-dose (co-formulated)  ACTs
artemether/lumefantrine#
arterolane/piperaquine
artesunate/amodiaquine (ASAQ)
artesunate/mefloquine (ASMQ)
artesunate/pyronaridine
piperaquine/dihydroartemisinin
Other combinations(not co-formulated)
artesunate/mefloquine
artesunate/SP
quinine/clindamycin
quinine/doxycycline
quinine/tetracycline
Babesiosis
clindamycin
Cilio-phora
Balantidiasis: tetracycline
Hetero-kont
Blastocystosis: metronidazole

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteAntiparasitics directed at excavata parasites (P01)DiscicristataTrypanosomiasisAfrican trypanosomiasis
ornithine (Eflornithine#)
arsenical (Atoxyl, Melarsoprol#, Tryparsamide)
benzamidine (Pentamidine#)
naphthalenesulfonate (Suramin#)
nitroimidazole (Fexinidazole†)
Chagas disease
nitroimidazole (Benznidazole#)
nitrofuran (Nifurtimox#)
Leishmaniasis
polyene (Amphotericin B#)
Pentavalent antimonials (Meglumine antimoniate#, Sodium stibogluconate)

benzamidine (Pentamidine#)
phosphorylcholine (Miltefosine)
neomycin (Paromomycin)
PAM
polyene (Amphotericin B)
TrichozoaGiardiasis
nitroimidazole (Metronidazole#, Tinidazole)
benzimidazole (Albendazole)
thiazolide (Nitazoxanide)
nitrofuran (Furazolidone)
aminoacridine (Quinacrine)
Trichomoniasis
nitroimidazole (Carnidazole, Metronidazole#, Tinidazole)
Dientamoebiasis
nitroimidazole (Metronidazole
Secnidazole)
oxyquinoline (Iodoquinol)
tetracycline (Doxycycline)
neomycin  (Paromomycin)

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteAntiparasitics – antiprotozoal agents – agents against amoebozoa/amebicide (P01)EntamoebaTissue amebicidesNitroimidazole derivatives
Metronidazole#
Tinidazole
Ornidazole
Nimorazole
Secnidazole
Azanidazole
Propenidazole
Other
isoquinoline (Emetine/Dehydroemetine)
Luminal amebicidesHydroxyquinoline derivatives
Cl (Chlorquinaldol)
Br (Tilbroquinol
Broxyquinoline)
I (Diiodohydroxyquinoline)
I, Cl (Clioquinol)
related: Chiniofon
Dichloroacetamide derivatives
Diloxanide#
Clefamide
Etofamide
Teclozan
Aminoglycoside
Paromomycin#
Other/ungrouped
arsenic (Arsthinol
Carbarsone
Difetarsone
Glycobiarsol)
phenanthroline (Phanquinone)
aminoacridine (Mepacrine)
quinazoline (Trimetrexate)
thiazole (Tenonitrozole)
sesquiterpene (Fumagillin)
Acanthamoeba
Propamidine
Chlorhexidine

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





